Background/Aims A clinical unmet need persists for medications capable of modulating the progression of primary sclerosing cholangitis (PSC). This study aimed to assess the clinical feasibility of HK-660S (beta-lapachone) in PSC.
Methods In this multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 trial, participants were assigned in a 2:1 ratio to receive either 100 mg of HK-660S or a placebo twice daily for 12 weeks. The primary outcomes were the reduction in serum alkaline phosphatase (ALP) levels and the percentage of participants showing improvements in PSC severity, as determined by magnetic resonance cholangiopancreatography with the Anali score. Secondary endpoints included changes in liver stiffness and adverse events.
Result s: The analysis included 21 patients, 15 receiving HK-660S, and six receiving a placebo. Improvements in the Anali score were observed in 13.3% of the HK-660S group, with no improvements in the placebo group. HK-660S treatment resulted in a 15.2% reduction in mean ALP levels, compared to a 6.6% reduction in the placebo group. A stratified ad-hoc analysis based on baseline ALP levels showed a statistically significant response in the HK-660S group among those with ALP levels greater than twice the upper limit of normal, with a 50% responder rate (p=0.05). Additionally, 26.7% of the HK-660S group showed improvements in the enhanced liver fibrosis score, with no improvements in the placebo group. HK-660S was generally well tolerated.
Conclusions HK-660S is well tolerated among patients with PSC and may improve bile duct strictures, decrease serum ALP levels, and reduce liver fibrosis (cris.nih.go.kr, Number KCT0006590).
Citations
Citations to this article as recorded by
Critical considerations in evaluating the therapeutic potential of HK-660S for primary sclerosing cholangitis: Letter to the editor on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: a randomized double-blind phase 2a tria Yizi He, Haifeng He, Qi Liang, Yongzhi Xie Clinical and Molecular Hepatology.2026; 32(1): e1. CrossRef
Pruritus in Chronic Cholestatic Liver Diseases, Especially in Primary Biliary Cholangitis: A Narrative Review Tatsuo Kanda, Reina Sasaki-Tanaka, Naruhiro Kimura, Hiroyuki Abe, Tomoaki Yoshida, Kazunao Hayashi, Akira Sakamaki, Takeshi Yokoo, Hiroteru Kamimura, Atsunori Tsuchiya, Kenya Kamimura, Shuji Terai International Journal of Molecular Sciences.2025; 26(5): 1883. CrossRef
Future Treatment Options for Managing Primary Sclerosing Cholangitis and Cholestatic Pruritus Taranika Sarkar Das, Raj Vuppalanchi Clinics in Liver Disease.2025; 29(4): 781. CrossRef
Background/Aims Little is known about the treatment or outcomes of hepatocellular carcinoma (HCC) complicated with bile duct invasion.
Methods A total of 247 consecutive HCC patients with bile duct invasion at initial diagnosis were retrospectively included.
Result s: The majority of patients had Barcelona Clinic Liver Cancer (BCLC) stage C HCC (66.8%). Portal vein tumor thrombosis was present in 166 (67.2%) patients. Median survival was 4.1 months. Various modalities of treatment were initially employed including surgical resection (10.9%), repeated transarterial chemoembolization (TACE) (42.5%), and conservative management (42.9%). Among the patients with obstructive jaundice (n=88), successful biliary drainage was associated with better overall survival rate. Among the patients with BCLC stage C, overall survival differed depending on the initial treatment for HCC; surgical resection, TACE, systemic chemotherapy, and conservative management showed overall survival rates of 11.5, 6.0 ,2.4, and 1.6 months, respectively. After adjusting for confounders, surgical resection and repeated TACE were significant prognostic factors for HCC patients with bile duct invasion (hazard ratios 0.47 and 0.39, Ps <0.001, respectively).
Conclusions The survival of HCC patients with bile duct invasion at initial diagnosis is generally poor. However, aggressive treatments for HCC such as resection or biliary drainage may be beneficial therapeutic options for patients with preserved liver function.
Citations
Citations to this article as recorded by
Prediction Model of Survival in Unresectable HCC with Central Bile Duct Invasion Receiving TACE After Biliary Drainage: TEMP Score Wenzhe Fan, Xinlin Zheng, Weihong Zhang, Bowen Zhu, Yanqin Wu, Miao Xue, Rong Tang, Zhen Huang, Liangliang Qiao, Mingjian Lu, Jian Wu, Yiyang Tang, Jinghua Chen, Shugui Huang, Mingjun Bai, Jiaping Li Journal of Hepatocellular Carcinoma.2025; Volume 12: 615. CrossRef
PBK as a novel biomarker performed excellent diagnostic and prognostic value in HCC associated with immune infiltration and methylation Beibei Lv, Fenna Zhang, Xinyi Zhang, Ziyi Wang, Shuai Hao, Na Ye, Na He Journal of Molecular Histology.2025;[Epub] CrossRef
Efficacy and safety of endoscopic ultrasound-guided hepaticogastrostomy for biliary drainage in hypervascular hepatocellular carcinoma: a retrospective study from Japan Kenneth Tachi, Kazuo Hara, Nozomi Okuno, Shin Haba, Takamichi Kuwahara, Toshitaka Fukui, Ahmed Mohammed Sadek, Hossam El-Din Shaaban Mahmoud Ibrahim, Minako Urata, Takashi Kondo, Yoshitaro Yamamoto Clinical Endoscopy.2025; 58(3): 448. CrossRef
Liver transplantation for spalt-like transcription factor 4-positive dual-phenotype hepatocellular carcinoma with microscopic bile duct tumor thrombus: a case report Songming Ding, Xiangyan Liu, Zhuoyi Wang, Shanjie Dong, Qinfen Xie, Shusen Zheng, Qiyong Li Endoscopy.2025; 57(S 01): E804. CrossRef
Hepatocellular carcinoma treated with radical resection after endoscopic diagnosis of the extent of bile duct invasion: A case report Yudai Sato, Tomoko Tadokoro, Hiroki Yamana, Hiraki Akai, Kei Takuma, Naoki Fujita, Mai Nakahara, Kyoko Oura, Koji Fujita, Joji Tani, Hideki Kamada, Asahiro Morishita, Hideki Kobara, Seiko Kagawa, Reiji Haba, Keiichi Okano, Tsutomu Masaki DEN Open.2024;[Epub] CrossRef
Transarterial Therapy for Hepatocellular Carcinoma Invading the Bile Duct Shiro Miyayama Interventional Radiology.2024; 9(1): 1. CrossRef
Outcomes of jaundice in advanced hepatocellular carcinoma – a sub-Saharan perspective PB Keshaw, M Bernon, M Emmamally, R Khan, UK Kotze, R Segobin, D Creamer, JEJ Krige, E Jonas, S Sobnach South African Journal of Surgery.2024; 62(2): 108. CrossRef
CORRECTION OF BILIARY HYPERTENSION IN THE TREATMENT OF PATIENTS WITH MECHANICAL JAUNDICE V. V. Boyko, Р. M. Smachilo, А. V. Maloshtan, V. M. Likhman, V. Yu. Brovkin Kharkiv Surgical School.2024; (1): 29. CrossRef
The Treatment of Hepatocellular Carcinoma with Major Vascular Invasion Tomoko Tadokoro, Joji Tani, Asahiro Morishita, Koji Fujita, Tsutomu Masaki, Hideki Kobara Cancers.2024; 16(14): 2534. CrossRef
DEB‐TACE versus cTACE for unresectable HCC with B1‐type bile duct invasion after successful biliary drainage: A propensity score matching analysis Wenzhe Fan, Xinlin Zheng, Xiao Zhao, Bowen Zhu, Yanqin Wu, Miao Xue, Rong Tang, Zhen Huang, Liangliang Qiao, Mingjian Lu, Yiyang Tang, Jian Wu, Jiaping Li Cancer Medicine.2024;[Epub] CrossRef
Effect of Biliary Drainage on the Prognosis of Patients with Hepatocellular Carcinoma and Bile Duct Invasion Keungmo Yang, Hyun Yang, Chang Wook Kim, Hee Chul Nam, Ji Hoon Kim, Ahlim Lee, U Im Chang, Jin Mo Yang, Hae Lim Lee, Jung Hyun Kwon, Soon Woo Nam, Soon Kyu Lee, Pil Soo Sung, Ji Won Han, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Hee Ye Gut and Liver.2024; 18(5): 877. CrossRef
Clinical Significance of Biliary Invasion at Diagnosis in Barcelona Clinic Liver Cancer Stage B–C Hepatocellular Carcinoma: A Nationwide Cohort Analysis in South Korea Chai Hong Rim, Won Sup Yoon, Sunmin Park Oncology.2024; : 1. CrossRef
Efficacy Analysis of PTCD + TACE vs PTCD + Apatinib in the Treatment of HCC with Obstructive Jaundice: A Retrospective Study Haohao Lu, Bin Liang, Xiangwen Xia, Chuansheng Zheng Anti-Cancer Agents in Medicinal Chemistry.2024; 24(17): 1241. CrossRef
Effect of Biliary Tract Invasion with Obstructive Jaundice on the Prognosis of Patients With Unresectable Hepatocellular Carcinoma Weiwei Jiang, Xiaobo Fu, Guobao Wang, Han Qi, Zixiong Chen, Fei Gao Academic Radiology.2023; 30(3): 483. CrossRef
Effect of percutaneous stenting strategy of unresectable malignant hilar biliary obstruction by three‐dimensional reconstruction volumetry Xiaobo Fu, Weiwei Jiang, Maoyuan Mu, Guobao Wang, Han Qi, Zixiong Chen, Mengxuan Zuo, Fei Gao Cancer Medicine.2023; 12(8): 9506. CrossRef
Prognosis value of microscopic bile duct invasion in hepatocellular carcinoma: A multicenter study Qizhen Huang, Kongying Lin, Zhipeng Lin, Hongbin Ji, Xiaoyu Zhou, Bin Wang, Yufeng Chen, Chuandong Sun, Shuguo Zheng, Jinhong Chen, Yifan Wang, Yanming Zhou, Weiping Zhou, Yongyi Zeng Cancer Medicine.2023; 12(22): 20821. CrossRef
Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma Osman Öcal, Michael Ingrisch, Muzaffer Reha Ümütlü, Bora Peynircioglu, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Bernhard Gebauer, Christoph J. Zech, Christian Sengel, Irene Bargellini, Roberto Iezzi, Alberto Benito, Maciej Pech, Peter Malfer British Journal of Cancer.2022; 126(2): 211. CrossRef
Postoperative adjuvant transarterial chemoembolization improves outcomes of hepatocellular carcinoma associated with bile duct tumor thrombus: a propensity score matching analysis Zhen-Hua Chen, Jin-Kai Feng, Ju-Xian Sun, Jia-Yi Wu, Wei-Xing Guo, Jie Shi, Yong-Gang Wei, Jian-Yin Zhou, Zhi-Bo Zhang, Mao-Lin Yan, Shu-Qun Cheng HPB.2022; 24(4): 547. CrossRef
Hepatocellular Carcinoma with Hepatic Duct Tumor Thrombus Shih-Feng Huang, Cheng-Chung Tsai Indian Journal of Surgery.2022; 84(S2): 434. CrossRef
Transarterial chemoembolization for hepatocellular carcinoma with vascular invasion Shiro Miyayama, Yasuaki Arai, Osamu Matsui The British Journal of Radiology.2022;[Epub] CrossRef
Prediction of effective percutaneous transhepatic biliary drainage in patients with hepatocellular carcinoma: A multi-central retrospective study Haofan Wang, Yitao Mao, Chunning Zhang, Xiaojun Hu, Bin Chen, Luwen Mu, Shuyi Wang, Yifen Lin, Zhanwang Xiang, Mingsheng Huang Liver Research.2022; 6(4): 269. CrossRef
Cholangioscopic biopsy sample detection of bile duct invasion by hepatocellular carcinoma: an underappreciated entity Teddy Sutardji Nagaria, Isaac Raijman, Mohamed O. Othman, Gary Lloyd Horn, John M. Vierling, Juhi Mahadik, Sadhna Dhingra iGIE.2022; 1(1): 62. CrossRef
Effectiveness, safety, and factors associated with the clinical success of endoscopic biliary drainage for patients with hepatocellular carcinoma: a retrospective multicenter study Akihiro Matsumi, Hironari Kato, Toru Ueki, Etsuji Ishida, Masahiro Takatani, Masakuni Fujii, Masaki Wato, Tatsuya Toyokawa, Ryo Harada, Hirofumi Tsugeno, Minoru Matsubara, Hiroshi Matsushita, Hiroyuki Okada BMC Gastroenterology.2021;[Epub] CrossRef
Hepatocellular carcinoma recurrence in the extrahepatic bile duct wall: A case report Taku Matsumoto, Toshihiko Yoshida, Takashi Yamagishi, Hironobu Goto, Dai Otsubo, Akinobu Furutani, Hisoka Yamane, Yasuhiro Fujino, Masahiro Tominaga Clinical Case Reports.2021; 9(3): 1561. CrossRef
A nomogram based on combining systemic and hepatic inflammation markers for predicting microscopic bile duct tumour thrombus in hepatocellular carcinoma Jun-Yi Wu, Ju-Xian Sun, Jia-Yi Wu, Xiao-Xiao Huang, Yan-Nan Bai, Yong-Yi Zeng, Zhi-Bo Zhang, Shu-Qun Cheng, Mao-Lin Yan BMC Cancer.2021;[Epub] CrossRef
Efficacy and Safety of Transarterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma Associated with Bile Duct Tumor Thrombus: A Real-World Retrospective Cohort Study Jin-Kai Feng, Ju-Xian Sun, Zong-Han Liu, Jing-Wen Gu, Zhen-Hua Chen, Chang Liu, Wei-Xing Guo, Jie Shi, Shu-Qun Cheng Cancer Management and Research.2021; Volume 13: 3551. CrossRef
Redefining Hepatocellular Carcinoma Staging Systems Based on the Bile Duct Invasion Status: A Multicenter Study Qizhen Huang, Yufeng Chen, Kongying Lin, Chuandong Sun, Shuguo Zheng, Jinhong Chen, Yifan Wang, Yanming Zhou, Weiping Zhou, Jingfeng Liu, Yongyi Zeng Frontiers in Oncology.2021;[Epub] CrossRef
The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment Young Youn Cho, Su Jong Yu, Jung-Ju Yoo, Minjong Lee, Dong Hyeon Lee, Yuri Cho, Kyoung Wan Yoon, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon Journal of Clinical Gastroenterology.2020; 54(4): 370. CrossRef
Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study
Qizhen Huang, Kongying Lin, Lei Wang, Jianxing Zeng, Hongzhi Liu, Zongren Ding, Yongyi Zeng, Jingfeng Liu Cancer Management and Research.2020; Volume 12: 9183. CrossRef
Glycochenodeoxycholic acid induces stemness and chemoresistance via the STAT3 signaling pathway in hepatocellular carcinoma cells Changying Shi, Jiamei Yang, Longmiao Hu, Boyi Liao, Liang Qiao, Weifeng Shen, Feng Xie, Guoqing Zhu Aging.2020; 12(15): 15546. CrossRef
Triple Covered Metal Stent Deployment Using Side-by-Side Technique for Hemobilia due to Hepatocellular Carcinoma (with Video) Takeshi Ogura, Tadahiro Yamada, Masanori Yamada, Saori Ueno, Kazuhide Higuchi Digestive Diseases.2020; 38(4): 348. CrossRef
Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion Taku Tanaka, Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Mitsuhiro Fujishiro Oncology.2020; 98(9): 621. CrossRef
FDG PET/CT Imaging of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus Wei Zhang, Cheng Fang, Huipan Liu, Yue Chen Clinical Nuclear Medicine.2019; 44(2): 130. CrossRef
Outcomes of major laparoscopic liver resection for hepatocellular carcinoma Hanisah Guro, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, YoungRok Choi, Sungho Kim, Kilhwan Kim, In Gun Hyun Surgical Oncology.2018; 27(1): 31. CrossRef
Percutaneous placement of self-expandable metallic stents in patients with obstructive jaundice due to hepatocellular carcinoma Hyun Pyo Hong, Kyungmin Park International Journal of Gastrointestinal Intervention.2018; 7(2): 85. CrossRef
First
Prev
